Regulatory Lilly bags FDA okay for Wegovy pill rival orforglipron PharmaphorumEli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk's first-to-market Wegovy pill.RegulatoryMetabolic & GLP-1Read full story pharminent April 1, 2026 (Last updated: April 1, 2026) Pharmaphorum Eli Lilly has claimed US approval for oral GLP-1 agonist orforglipron, setting up a market clash with Novo Nordisk’s first-to-market Wegovy pill. RegulatoryMetabolic & GLP-1Read full story Please leave this field emptySign up to receive free daily digest Check your inbox or spam folder to confirm your subscription. Post navigation Previous: Eli Lilly’s Oral Obesity Pill Approved, Kicking Off Renewed Novo RivalryNext: FDA approves Lilly obesity pill, triggering battle with Novo Nordisk Related Stories Regulatory Outlook Therapeutics Secures FDA Approval for LYTENAVA pharminent July 31, 2026 Regulatory Outlook finally claims FDA approval for AMD drug pharminent July 27, 2026 Regulatory Outlook Therapeutics wins FDA approval for Lytenava in wet AMD pharminent July 27, 2026
